December 10, 2022 11:30 AM EST
R&D
Pharma
Cell/Gene Tx

#ASH22: J&J touts first PhII re­sults of next-gen mul­ti­ple myelo­ma an­ti­body

Kyle LaHucik

Senior Reporter

NEW OR­LEANS — A day af­ter sub­mit­ting its ap­pli­ca­tion to the FDA to use its drug tal­que­tam­ab for treat­ment of re­lapsed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

A service from the Financial Times